The blockade of EGFR as an important therapeutical intervention alone and in combination with chemotherapy has already been investigated in soft tissue sarcomas (including uterine leiomyosarcomas) using in vitro and in vivo (animal model) experiments with promising results [32]. Here, EGFR is linked to soft tissue sarcoma.